Project Grant K22AI177518

Award Date 8/21/24
Completion Date 7/31/26
Dollars Obligated $160K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,269,762 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University. The grant will fund the development of a microfluidic platform called SECRE (Secretion-Enabled Cell Ranking and Enrichment) to enable high-performance sorting of immune cells based on their secretion patterns. This technology will be leveraged to conduct genome-wide CRISPR activation and/or...
The federal Project Grant award R35HL177401 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,183,648.00 in funding to Northwestern University over an 8-year period starting February 1, 2025. The grant supports research to investigate the role of macrophage phagocytes in cardiac inflammation and disease, with the goal of identifying new therapeutic approaches for heart failure and acute ischemic injury. Key objectives include...
The federal Project Grant award R21AI182804 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the regulation of metabolic adaptation in effector CD8 T cells during chronic viral infection. The $189,713 award, effective from November 12, 2024 to October 31, 2026, will be conducted by Northwestern University to investigate the role of the IL-21-PIM1 signaling axis in...
This federal Project Grant award of $796,083.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a translational epidemiologic study investigating single-cell transcriptomic and gene-regulatory profiles of immune cells in human peripheral blood mononuclear cells (PBMCs) and plaque associated with atherosclerotic cardiovascular disease (ASCVD). The study aims to determine if inflammatory monocyte polarization,...
The federal Project Grant award R01AI182143, totaling $506,394.00, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to define the molecular and cellular mechanisms by which bacterial cholesterol-dependent cytolysins (CDCs) can reorganize host organelles and activate the NLRP3 inflammasome signaling pathway. This research aims to help characterize CDCs as potential...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $606,501.00 to Northwestern University to elucidate the epigenetic control of germinal center B cell differentiation by the BAF chromatin remodeling complex. The research aims to examine the roles of inflammatory signatures associated with the loss of the ARID1A subunit in disrupting germinal center...
This federal Project Grant award of $479,249, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to study the molecular mechanisms regulating neutrophil proinflammatory activity in sepsis. The key objectives are to: Determine the molecular basis of neutrophil A20 signaling in regulating neutrophil proinflammatory function under septic conditions. Utilize two-photon intravital...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $244,440.00 to the Albert Einstein College of Medicine to conduct research on how Ly6C+ monocytes respond to and help clear microbial pathogen infections. The research aims to define the chemotactic cues, receptors, and mechanisms involved in how these monocytes home to infection sites and form stable clusters to deliver local...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA Program 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders, provides $9,631,026 to Northwestern University to conduct a comprehensive analysis of the impact of atherosclerosis on the brain's microvasculature in the context of Alzheimer's disease (AD). The research aims to deepen the understanding of the relationship between vascular health and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, provides $189,150.00 to the University of Colorado-Denver to identify new mediators of proinflammatory cytokine signaling. The project aims to perform genome-wide genetic screens to identify factors that mediate the inhibitory effects of cytokines like IL-1β and TNFα on the AKT signaling pathway, which regulates various physiological...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $160,000 in funding to Northwestern University to develop and evaluate engineered cytokine constructs that target lipid-laden macrophages for the treatment of atherosclerosis. The key objectives are to: 1) elucidate the molecular mechanisms by which the engineered cytokine constructs suppress inflammation in atherosclerosis, 2) engineer additional functionalities into the constructs, and 3) assess the generalizability of the platform to other cytokine payloads. This research aims to advance the development of targeted cytokine therapies that can provide localized immunomodulation with minimal off-target effects, with potential applications in other diseases involving lipid-laden macrophages. The award period runs from August 2024 to July 2026.

Generated 7/1/25, 3:51 AM